


## Another Promising Candidate in the Fight Against COVID-19



Our July 4th celebrations last weekend looked very different from years past, as America waits in anticipation to declare independence from the coronavirus.

While a number of vaccine candidates continue to make headlines as companies race to develop an effective immunization against COVID-19, scientists are making equally rapid progress on other therapies, including a cutting-edge antibody cocktail.

Just yesterday, the New York-based biotechnology company Regeneron [announced the beginning of a Phase 3 trial](#) to test whether the company's double antibody cocktail can prevent and treat COVID-19 infection. The trial will take place in 100 locations with over 2,000 patients across the U.S.

Soon after the announcement of the Phase 3 trial, the U.S. government threw their weight – and funding – behind the innovative therapy. On

Tuesday, Regeneron [signed a \\$450 million contract](#) with the U.S. government to manufacture and supply the double-antibody cocktail, should it receive regulatory approval.

Regeneron's story provides a glimpse into the broader clinical trials process – and the public-private collaboration which supports it – occurring in communities large and small throughout the United States.

American biomedical innovation is one of this nation's greatest strengths, and the numbers behind the search for coronavirus treatments and cures tell us this story. Right now, there are [513 clinical trials happening in hospitals and medical facilities in all 50 states](#). Those trials are evaluating everything from new vaccines, to the use of existing innovative medicines, to the efficacy of different therapies.

The trials are sponsored by large pharmaceutical companies, small biotech operations, academic institutions, and hospitals alike. With the most promising clinical efforts backed by the U.S. government as part of Operation Warp Speed, it's clear everyone shares one common goal: ending the spread of COVID-19.

With the brightest scientific minds, the most innovative companies, and the backing of the U.S. government, we are hopeful that goal will soon be realized.

–Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center